Document Detail


Bevacizumab in the treatment of metastatic breast cancer: three case reports.
MedLine Citation:
PMID:  21490480     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Case reports are presented for three patients with metastatic breast cancer who received first-line treatment with bevacizumab in combination with taxanes in clinical trials. Two patients showed peak reductions in lesion size of 49 and 70%, respectively. In one patient, subsequent treatment with bevacizumab in combination with capecitabine [Xeloda (after discontinuation of paclitaxel due to asthenia)] yielded peak reductions in target lesion size of 78%. One patient experienced a progression-free survival time of 16 months. In all three patients, bevacizumab was well tolerated and mostly displayed only mild toxicities.
Authors:
Ana Ferreira; Cláudia Vieira; Ana Rodrigues; Deolinda Pereira; Helena Rodrigues; Cristina Dávila; Sandra Bento
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Current opinion in oncology     Volume:  23 Suppl     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-14     Completed Date:  2011-06-21     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S11-9     Citation Subset:  IM    
Affiliation:
Hospital Distrital de Santarém, Avenida Bernardo Santereno, 2000 Santarém, Portugal.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / administration & dosage*,  therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use*
Bone Neoplasms / radiotherapy,  secondary,  surgery
Breast Neoplasms / drug therapy*,  pathology,  radiotherapy,  surgery
Carcinoma in Situ / drug therapy*,  pathology,  radiotherapy,  surgery
Carcinoma, Ductal / drug therapy*,  pathology,  radiotherapy,  secondary*,  surgery
Combined Modality Therapy
Deoxycytidine / administration & dosage,  adverse effects,  analogs & derivatives
Disease-Free Survival
Female
Fluorouracil / administration & dosage,  adverse effects,  analogs & derivatives
Humans
Kidney Neoplasms / radiotherapy,  secondary,  surgery
Liver Neoplasms / radiotherapy,  secondary,  surgery
Lung Neoplasms / radiotherapy,  secondary,  surgery
Lymphatic Metastasis
Paclitaxel / adverse effects
Survival Analysis
Taxoids / administration & dosage
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Taxoids; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab; 33069-62-4/Paclitaxel; 51-21-8/Fluorouracil; 6804DJ8Z9U/capecitabine; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of estimated glomerular filtration rate reporting on nephrology referrals: a review of the li...
Next Document:  Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanc...